TRINTELLIX® (vortioxetine) is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

Savings & Support

Concerned about cost and access? We're here for you and your patients

~85% of commercial lives without PA

TRINTELLIX is available for ~85% of commercially insured patients in the United States without prior authorization (PA)*

*Formulary data are provided by Fingertip Formulary® and are current as of September 2022. Check patient’s individual health plan for coverage and cost information, which may change without notice.


Eligible patients pay as little as $10 for either a 30-day or 90-day prescription. Savings of up to $100 per 30-day or $300 per 90-day prescription, with a maximum total savings of up to $1,300 over one year.
Restrictions apply.

TRINTELLIX (vortioxetine) Savings Card

Only commercially insured patients ages 18 or older with a valid prescription are eligible for the TRINTELLIX Savings Card. See full Eligibility Requirements and Terms & Conditions on the savings card.

Request Samples

Is your office running low on TRINTELLIX samples? Just visit MySampleCloset and
follow the steps below.

  • Login or register to create a new account (upon login, you may be prompted to complete a few security questions)
  • View the list of products and select TRINTELLIX
  • Place and submit your order. Maximum order quantities are listed on the site, one order may be placed per month.

Please note that when a TRINTELLIX sample order is placed on the MySampleCloset website, your local Takeda representative will be notified so that they can expedite delivery by bringing them to your office personally. If the representative is unable to deliver your order, the samples will be shipped to your office.

Prior Authorization Assistance

For patients who require PA, PARx Solutions may be able to help. The user-friendly portal helps initiate and manage PAs while also helping ensure the accuracy of administrative components of the PA submission.

Submit a PA today at

Quote: "Feeling like I have support goes a long way."

Get to know the tAccess support program:

When enrolled, patients can customize their experience through support tools like:

tAccess Support Program

Mobile wallet

Must meet eligibility requirements.

Informative emails

Inspiring texts and refill reminders

Chats with a tAccess advisor

1-844-654-TRIN - 8:00 am - 8:00 pm ET M-F (1-844-654-8746)

We are committed to partnering with you to help provide support for MDD patients:

  • Education around the symptoms of Major Depressive Disorder
  • Encouragement of dialogue with you, their healthcare professional
  • Tips and tools that reinforce the conversations you have with your patients


By clicking “Continue,” you will be leaving a Takeda and Lundbeck controlled website for a third-party website.

Please note that neither Takeda nor Lundbeck is responsible or liable for any third-party website, and the website may not be appropriate for all audiences.

  1. Trintellix (vortioxetine) prescribing information. Takeda Pharmaceuticals.
  2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of LuAA21004 in patients with Major Depressive Disorder. Int J Neuropsychopharmacol. 2012;15(5):589-600.
  3. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with Major Depressive Disorder. J Clin Psychiatry. 2012;73(7):953-959.
  4. Boulenger J-P, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with Major Depressive Disorder. Int Clin Psychopharmacol. 2014;29(3):138-149.
  5. Mahableshwarkar AR, Jacobsen P, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine‑referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015;232(12):2061-2070.
  6. Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with Major Depressive Disorder. J Clin Psychiatry. 2015;76(5):575-582.
  7. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with Major Depressive Disorder. Int Clin Psychopharmacol. 2012;27(4):215-223.
  8. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-1567.
  9. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in Major Depressive Disorder. Neuropsychopharmacology. 2015;40(8):2025-2037.
  10. Data on file. Takeda Pharmaceuticals.
  11. Data on file. Lundbeck.
  12. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with Major Depressive Disorder. J Psychopharmacol. 2012;26(11):1408-1416.
  13. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well‑treated Major Depressive Disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036-2048.
  14. Kambeitz JP, Howes OD. The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015;186:358-366.
  15. American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5®). Arlington, VA: American Psychiatric Association; 2013:155-188.
  16. ICD-10-CM Tabular list of diseases and injuries. Centers for Medicare & Medicaid Services. Published 2022. Accessed August 19, 2022.